Precision BioSciences earnings beat by $0.56, revenue fell short of estimates
Precision BioSciences (DTIL) reported Q3 EPS of -$0.28, beating estimates by $0.56, but revenue of $1.25M missed expectations. Stock is down 7.21% over 3 months, up 4.48% over 12 months. InvestingPro rates its financial health as 'fair performance'.
How this was made
The 30-second read
Why it matters
DTIL’s EPS beat versus a revenue miss creates a two-sided setup that can lead to volatile positioning into the next earnings cycle.
Market read
Traders can use the EPS and revenue deltas versus consensus to reassess near-term expectations for DTIL, but the lack of guidance limits forward decision-making.
What to watch
The article does not mention cash balance, guidance, or pipeline updates, which are often more important than EPS for biotech valuation.
Background
The piece summarizes Precision BioSciences’ Q3 results versus analyst consensus and notes recent EPS revision activity and the stock’s recent performance.
Ticker impact
Precision BioSciences reported Q3 EPS of -0.28, beating the -0.84 estimate, while revenue missed at $1.25M vs $1.38M consensus.
Likely choppy trading as the market weighs EPS beat against weaker-than-expected revenue.
The article provides both EPS and revenue vs consensus, which typically drives near-term repricing, but no guidance or other incremental catalyst is included.
Market effects
Limited read-through to biotech broadly, since this is a single-company microcap-style earnings datapoint with no sector-wide catalyst.
Minimal, as the story is company-specific and not tied to a macro release.
Low, no international or cross-market linkage beyond general risk sentiment.
Counterpoint
The EPS beat could be driven by timing or non-recurring items, so traders may discount it if revenue weakness signals ongoing demand or funding pressure.
Key entities
- companyPrecision BioSciences
NASDAQ-listed biotech whose Q3 EPS and revenue were reported versus consensus.
- tickerDTIL
Precision BioSciences common stock ticker referenced in the article.
